{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T19:58:25Z","timestamp":1782417505595,"version":"3.54.5"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100015068","name":"Universidade de Santiago de Compostela","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100015068","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"DOI":"10.1007\/s13346-026-02130-9","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T17:27:56Z","timestamp":1781976476000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Oral nanoparticle-encapsulated enzyme replacement therapy for mucopolysaccharidosis type I (MPS-I): a proof of concept study"],"prefix":"10.1007","author":[{"given":"Jose-Victor","family":"\u00c1lvarez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lluis","family":"Lis-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Pena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana-Bel\u00e9n","family":"Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"D\u00edaz-Tom\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selene Cuello","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"L\u00f3pez-Valverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno-Kotska","family":"Rodi\u00f1o-Janeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crist\u00f3bal","family":"Col\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asteria","family":"Luzardo-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Jose","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco-Javier","family":"Otero-Espinar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Luz","family":"Couce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"key":"2130_CR1","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/gim.2014.25","volume":"16","author":"M Beck","year":"2014","unstructured":"Beck M, Arn P, Giugliani R, Muenzer J, Okuyama T, Taylor J, et al. The natural history of MPS I: global perspectives from the MPS I Registry. Genet Med. 2014;16:759\u201365.","journal-title":"Genet Med"},{"key":"2130_CR2","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1002\/jimd.12431","volume":"44","author":"SDK Kingma","year":"2021","unstructured":"Kingma SDK, Jonckheere AI. MPS I: early diagnosis, bone disease and treatment, where are we now? J Inherit Metab Dis. 2021;44:1289\u2013310.","journal-title":"J Inherit Metab Dis"},{"key":"2130_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22157888","volume":"22","author":"CS Hampe","year":"2021","unstructured":"Hampe CS, Yund BD, Orchard PJ, Lund TC, Wesley J, McIvor RS. Differences in MPS I and MPS II disease manifestations. Int J Mol Sci. 2021;22:7888.","journal-title":"Int J Mol Sci"},{"key":"2130_CR4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s13023-022-02486-4","volume":"17","author":"A R\u00f3\u017cd\u017cy\u0144ska-\u015awi\u0105tkowska","year":"2022","unstructured":"R\u00f3\u017cd\u017cy\u0144ska-\u015awi\u0105tkowska A, Zieli\u0144ska A, Tylki-Szyma\u0144ska A. Comparison of growth dynamics in different types of MPS: an attempt to explain the causes. Orphanet J Rare Dis. 2022;17:339.","journal-title":"Orphanet J Rare Dis"},{"key":"2130_CR5","doi-asserted-by":"crossref","unstructured":"Kubaski F, de Oliveira Poswar F, Michelin-Tirelli K, Matte U da, Horovitz S, Barth DD. AL et al Mucopolysaccharidosis Type I Diagnostics (Basel). 2020;10:161.","DOI":"10.3390\/diagnostics10030161"},{"key":"2130_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1750-1172-3-24","volume":"3","author":"D Moore","year":"2008","unstructured":"Moore D, Connock MJ, Wraith E, Lavery C. The prevalence of and survival in mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie syndromes in the UK. Orphanet J Rare Dis. 2008;3:24.","journal-title":"Orphanet J Rare Dis"},{"key":"2130_CR7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s13023-021-01880-8","volume":"16","author":"Y Puckett","year":"2021","unstructured":"Puckett Y, Mallorga-Hern\u00e1ndez A, Monta\u00f1o AM. Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities. Orphanet J Rare Dis. 2021;16:241.","journal-title":"Orphanet J Rare Dis"},{"key":"2130_CR8","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s00381-017-3476-0","volume":"33","author":"A Dalla Corte","year":"2017","unstructured":"Dalla Corte A, de Souza CFM, An\u00e9s M, Giugliani R. Hydrocephalus and mucopolysaccharidoses: what do we know and what do we not know? Childs Nerv Syst. 2017;33:1073\u201380.","journal-title":"Childs Nerv Syst"},{"key":"2130_CR9","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.3390\/jcm8091467","volume":"8","author":"S Tomatsu","year":"2019","unstructured":"Tomatsu S, Pitz S, Hampel U. Ophthalmological findings in mucopolysaccharidoses. J Clin Med. 2019;8:1467.","journal-title":"J Clin Med"},{"key":"2130_CR10","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1016\/j.bbmt.2019.02.012","volume":"25","author":"M Taylor","year":"2019","unstructured":"Taylor M, Khan S, Stapleton M, Wang J, Chen J, Wynn R, et al. Hematopoietic stem cell transplantation for mucopolysaccharidoses; past, present, and future. Biol Blood Marrow Transpl. 2019;25:e226\u201346.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2130_CR11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13052-018-0562-1","volume":"44","author":"D Concolino","year":"2018","unstructured":"Concolino D, Deodato F, Parini R. Enzyme replacement therapy: efficacy and limitations. Ital J Pediatr. 2018;44:120.","journal-title":"Ital J Pediatr"},{"key":"2130_CR12","volume":"2019","author":"E Jameson","year":"2019","unstructured":"Jameson E, Jones S, Remmington T. Enzyme replacement therapy with laronidase (Aldurazyme\u00ae) for treating mucopolysaccharidosis type I. Cochrane Database Syst Rev. 2019;2019:CD009354.","journal-title":"Cochrane Database Syst Rev"},{"key":"2130_CR13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1089\/genbio.2021.0013","volume":"1","author":"AC Puhl","year":"2022","unstructured":"Puhl AC, Ekins S. Advancing the research and development of enzyme replacement therapies for lysosomal storage diseases. GEN Biotechnol. 2022;1:156\u201362.","journal-title":"GEN Biotechnol"},{"key":"2130_CR14","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/s10038-019-0662-9","volume":"64","author":"HH Chen","year":"2019","unstructured":"Chen HH, Sawamoto K, Mason RW, Kobayashi H, Yamaguchi S, Suzuki Y, et al. Enzyme replacement therapy for mucopolysaccharidoses; past, present, and future. J Hum Genet. 2019;64:1153\u201371.","journal-title":"J Hum Genet"},{"key":"2130_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21082975","volume":"21","author":"R Parini","year":"2020","unstructured":"Parini R, Deodato F. Intravenous enzyme replacement therapy in mucopolysaccharidoses: clinical effectiveness and limitations. Int J Mol Sci. 2020;21:2975.","journal-title":"Int J Mol Sci"},{"key":"2130_CR16","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1007\/s12035-016-9849-7","volume":"54","author":"Y Wang","year":"2017","unstructured":"Wang Y, MacDonald RG, Thinakaran G, Kar S. Insulin-like growth factor-II\/cation-independent mannose 6-phosphate receptor in neurodegenerative diseases. Mol Neurobiol. 2017;54:2636\u201358.","journal-title":"Mol Neurobiol"},{"key":"2130_CR17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3390\/biom11020189","volume":"11","author":"CS Hampe","year":"2021","unstructured":"Hampe CS, Wesley J, Lund TC, Orchard PJ, Polgreen LE, Eisengart JB, et al. Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement. Biomolecules. 2021;11:189.","journal-title":"Biomolecules"},{"key":"2130_CR18","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00431-011-1644-x","volume":"171","author":"K D\u2019Aco","year":"2012","unstructured":"D\u2019Aco K, Underhill L, Rangachari L, Arn P, Cox GF, Giugliani R, et al. Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry. Eur J Pediatr. 2012;171:911\u20139.","journal-title":"Eur J Pediatr"},{"key":"2130_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-6-55","volume":"6","author":"MH de Ru","year":"2011","unstructured":"de Ru MH, Boelens JJ, Das AM, Jones SA, van der Lee JH, Mahlaoui N, et al. Enzyme replacement therapy and\/or hematopoietic stem cell transplantation at diagnosis in patients with Mucopolysaccharidosis Type I: results of a European consensus procedure. Orphanet J Rare Dis. 2011;6:55.","journal-title":"Orphanet J Rare Dis"},{"key":"2130_CR20","first-page":"103","volume":"2","author":"D Sillence","year":"2012","unstructured":"Sillence D, Waters K, Donaldson S, Shaw PJ, Ellaway C. Combined enzyme replacement therapy and hematopoietic stem cell transplantation in Mucopolysacharidosis Type VI. JIMD Rep. 2012;2:103\u20136.","journal-title":"JIMD Rep"},{"key":"2130_CR21","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ymgme.2016.02.006","volume":"117","author":"Y Xue","year":"2016","unstructured":"Xue Y, Richards SM, Mahmood A, Cox GF. Effect of anti-laronidase antibodies on efficacy and safety of laronidase enzyme replacement therapy for MPS I: a comprehensive meta-analysis of pooled data from multiple studies. Mol Genet Metab. 2016;117:419\u201326.","journal-title":"Mol Genet Metab"},{"key":"2130_CR22","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1681\/ASN.2018030329","volume":"29","author":"M Lenders","year":"2018","unstructured":"Lenders M, Brand E. Effects of enzyme replacement therapy and antidrug antibodies in patients with Fabry Disease. J Am Soc Nephrol. 2018;29:2265\u201378.","journal-title":"J Am Soc Nephrol"},{"key":"2130_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.965089","volume":"9","author":"SR Wood","year":"2022","unstructured":"Wood SR, Bigger BW. Delivering gene therapy for mucopolysaccharide diseases. Front Mol Biosci. 2022;9:965089.","journal-title":"Front Mol Biosci"},{"key":"2130_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2021.618360","volume":"14","author":"LR Belur","year":"2021","unstructured":"Belur LR, Romero M, Lee J, Podetz-Pedersen KM, Nan Z, Riedl MS, et al. Comparative effectiveness of intracerebroventricular, intrathecal, and intranasal routes of AAV9 vector administration for genetic therapy of neurologic disease in murine Mucopolysaccharidosis Type I. Front Mol Neurosci. 2021;14:618360.","journal-title":"Front Mol Neurosci"},{"key":"2130_CR25","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.3390\/ijms23094785","volume":"23","author":"P Zapolnik","year":"2022","unstructured":"Zapolnik P, Pyrkosz A. Nanoemulsions as gene delivery in Mucopolysaccharidosis Type I-a mini-review. Int J Mol Sci. 2022;23:4785.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2130_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-025-01919-7","volume":"51","author":"W Zhang","year":"2025","unstructured":"Zhang W, Huang Y, Su X, et al. Allogeneic hematopoietic stem cell transplantation for mucopolysaccharidosis patients: A single-center experience and assessment of quality of life. Ital J Pediatr. 2025;51(1):83. https:\/\/doi.org\/10.1186\/s13052-025-01919-7.","journal-title":"Ital J Pediatr"},{"key":"2130_CR27","doi-asserted-by":"publisher","first-page":"124355","DOI":"10.1016\/j.ijpharm.2024.124355","volume":"660","author":"RS Schuh","year":"2024","unstructured":"Schuh RS, Franceschi EP, Brum BB, Fachel FNS, Poletto \u00c9, Vera LNP, et al. Laronidase-loaded liposomes reach the brain and other hard-to-treat organs after noninvasive nasal administration. Int J Pharm. 2024;660:124355.","journal-title":"Int J Pharm"},{"key":"2130_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3410","volume":"24","author":"LNP Vera","year":"2022","unstructured":"Vera LNP, Schuh RS, Fachel FNS, Poletto E, Piovesan E, Kubaski F, et al. Brain and visceral gene editing of mucopolysaccharidosis I mice by nasal delivery of the CRISPR\/Cas9 system. J Gene Med. 2022;24:e3410.","journal-title":"J Gene Med"},{"issue":"3","key":"2130_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1684","volume":"13","author":"I Abasolo","year":"2021","unstructured":"Abasolo I, et al. Nanotechnology-based approaches for treating lysosomal storage disorders, a focus on Fabry disease. WIREs Nanomed Nanobiotechnol. 2021;13(3):e1684.29.","journal-title":"WIREs Nanomed Nanobiotechnol"},{"key":"2130_CR30","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.3390\/ijms20082014","volume":"20","author":"L Rigon","year":"2019","unstructured":"Rigon L, et al. Targeting Brain Disease in MPSII: Preclinical Evaluation of IDS-Loaded PLGA Nanoparticles. Int J Mol Sci. 2019;20:2014.","journal-title":"Int J Mol Sci"},{"key":"2130_CR31","doi-asserted-by":"publisher","first-page":"10289","DOI":"10.1038\/s41598-023-37138-5","volume":"13","author":"L Badenetti","year":"2023","unstructured":"Badenetti L, et al. A novel CRISPR\/Cas9-based iduronate-2-sulfatase (IDS) knockout human neuronal cell line reveals earliest pathological changes. Sci Rep. 2023;13:10289.","journal-title":"Sci Rep"},{"key":"2130_CR32","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s11095-018-2503-5","volume":"35","author":"RS Schuh","year":"2018","unstructured":"Schuh RS, et al. Nasal Administration of Cationic Nanoemulsions as Nucleic Acids Delivery Systems Aiming at Mucopolysaccharidosis Type I Gene Therapy. Pharm Res. 2018;35:221.","journal-title":"Pharm Res"},{"key":"2130_CR33","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.omtm.2023.05.010","volume":"29","author":"S Kida","year":"2023","unstructured":"Kida S, et al. Enzyme replacement with transferrin receptor-targeted \u03b1-L-iduronidase rescues brain pathology in mucopolysaccharidosis I mice. Mol Ther Methods Clin Dev. 2023;29:439\u201349.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2130_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11100522","volume":"11","author":"J \u00c1lvarez","year":"2019","unstructured":"\u00c1lvarez J, Herrero Filgueira C, Gonz\u00e1lez A, Col\u00f3n Mejeras C, Beiras Iglesias A, Tomatsu S, et al. Enzyme-loaded gel core nanostructured lipid carriers to improve treatment of Lysosomal Storage Diseases: Formulation and in vitro cellular studies of Elosulfase Alfa-loaded systems. Pharmaceutics. 2019;11:522.","journal-title":"Pharmaceutics"},{"key":"2130_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184610","volume":"20","author":"JV \u00c1lvarez","year":"2019","unstructured":"\u00c1lvarez JV, Bravo SB, Garc\u00eda-Vence M, De Castro MJ, Luzardo A, Col\u00f3n C, et al. Proteomic analysis in Morquio A cells treated with immobilized enzymatic replacement therapy on nanostructured lipid systems. Int J Mol Sci. 2019;20:4610.","journal-title":"Int J Mol Sci"},{"key":"2130_CR36","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ejpb.2018.10.017","volume":"133","author":"A Gordillo-Galeano","year":"2018","unstructured":"Gordillo-Galeano A, Mora-Huertas CE. Solid lipid nanoparticles and nanostructured lipid carriers: A review emphasizing on particle structure and drug release. Eur J Pharm Biopharm. 2018;133:285\u2013308.","journal-title":"Eur J Pharm Biopharm"},{"issue":"2","key":"2130_CR37","doi-asserted-by":"publisher","first-page":"100406","DOI":"10.1016\/j.xpro.2021.100406","volume":"2","author":"IJ Bravo","year":"2021","unstructured":"Bravo IJ, Kim M, Benayoun AB. Protocol for isolation of adult mouse ear pinnae- derived primary fibroblasts. STAR Protoc. 2021;2(2):100406.","journal-title":"STAR Protoc"},{"key":"2130_CR38","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.aca.2016.06.054","volume":"936","author":"C Auray-Blais","year":"2016","unstructured":"Auray-Blais C, Lavoie P, Tomatsu S, Valayannopoulos V, Mitchell JJ, Raiman J, et al. UPLC-MS\/MS detection of disaccharides derived from glycosaminoglycans as biomarkers of mucopolysaccharidoses. Anal Chim Acta. 2016;936:139\u201348.","journal-title":"Anal Chim Acta"},{"key":"2130_CR39","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/jfb5020043","volume":"5","author":"M Lehock\u00fd","year":"2014","unstructured":"Lehock\u00fd M, Humpol\u00ed\u010dek P, S\u00e1ha P. HaCaT keratinocytes response on antimicrobial atelocollagen Sub-800 strates: Extent of cytotoxicity, cell viability and proliferation. J Funct Biomater. 2014;5:43\u201357. https:\/\/doi.org\/10.3390\/jfb5020043.","journal-title":"J Funct Biomater"},{"key":"2130_CR40","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1021\/acs.molpharmaceut.6b01165","volume":"14","author":"I Lozoya-Agullo","year":"2017","unstructured":"Lozoya-Agullo I, Ara\u00fajo F, Gonz\u00e1lez-\u00c1lvarez I, Merino-Sanju\u00e1n M, Gonz\u00e1lez-\u00c1lvarez M, Bermejo M, et al. Usefulness of Caco-2\/HT29-MTX and Caco-2\/HT29-MTX\/Raji B coculture models to predict intestinal and colonic permeability compared to Caco-2 monoculture. Mol Pharm. 2017;14:1264\u201370.","journal-title":"Mol Pharm"},{"key":"2130_CR41","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.3390\/ijms25063232","volume":"25","author":"SB \u00c1lvarez JVictor, Bravo","year":"2024","unstructured":"\u00c1lvarez JVictor, Bravo SB, Chantada-V\u00e1zquez MP, Pena C, Col\u00f3n C, Tomatsu S, et al. Morquio A Syndrome: Identification of Differential Patterns of Molecular Pathway Interactions in Bone Lesions. Int J Mol Sci. 2024;25:3232.","journal-title":"Int J Mol Sci"},{"key":"2130_CR42","doi-asserted-by":"publisher","first-page":"6165","DOI":"10.3390\/ijms22116165","volume":"22","author":"JV \u00c1lvarez","year":"2021","unstructured":"\u00c1lvarez JV, Bravo SB, Chantada-V\u00e1zquez MP, Barbosa-Gouveia S, Col\u00f3n C, L\u00f3pez-Suarez O, et al. Plasma Proteomic Analysis in Morquio A Disease. Int J Mol Sci. 2021;22:6165.","journal-title":"Int J Mol Sci"},{"key":"2130_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22010226","volume":"22","author":"VJ \u00c1lvarez","year":"2020","unstructured":"\u00c1lvarez VJ, Bravo SB, Chantada-Vazquez MP, Col\u00f3n C, De Castro MJ, Morales M, et al. Characterization of new proteomic biomarker candidates in Mucopolysaccharidosis type IVA. Int J Mol Sci. 2020;22:226.","journal-title":"Int J Mol Sci"},{"key":"2130_CR44","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3390\/ijms22010226","volume":"22","author":"VJ \u00c1lvarez","year":"2020","unstructured":"\u00c1lvarez VJ, Bravo SB, Chantada-Vazquez MP, Col\u00f3n C, De Castro MJ, Morales M, et al. Characterization of New Proteomic Biomarker Candidates in Mucopolysaccharidosis Type IVA. Int J Mol Sci. 2020;22:226.","journal-title":"Int J Mol Sci"},{"key":"2130_CR45","doi-asserted-by":"publisher","first-page":"e0294236","DOI":"10.1371\/journal.pone.0294236","volume":"18","author":"D Tang","year":"2023","unstructured":"Tang D, Chen M, Huang X, Zhang G, Zeng L, Zhang G, et al. SRplot: a free online platform for data visualization and graphing. PLoS One. 2023;18:e0294236.","journal-title":"PLoS One"},{"key":"2130_CR46","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.omtm.2023.05.010","volume":"29","author":"S Kida","year":"2023","unstructured":"Kida S, Koshimura Y, Yoden E, Yoshioka A, Morimoto H, Imakiire A, et al. Enzyme replacement with transferrin receptor-targeted \u03b1-L-iduronidase rescues brain pathology in Mucopolysaccharidosis I mice. Mol Ther Methods Clin Dev. 2023;29:439\u201349.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2130_CR47","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s11095-014-1508-y","volume":"32","author":"FQ Mayer","year":"2015","unstructured":"Mayer FQ, Adorne MD, Bender EA, de Carvalho TG, Dilda AC, Beck RCR, et al. Laronidase-Functionalized Multiple-Wall Lipid-Core Nanocapsules: Promising Formulation for a More Effective Treatment of Mucopolysaccharidosis Type I. Pharm Res. 2015;32:941\u201354.","journal-title":"Pharm Res"},{"key":"2130_CR48","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/jimd.12414","volume":"44","author":"SC Hurt","year":"2021","unstructured":"Hurt SC, Dickson PI, Curiel DT. Mucopolysaccharidoses type I gene therapy. J Inherit Metab Dis. 2021;44:1088\u201398.","journal-title":"J Inherit Metab Dis"},{"key":"2130_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-39939-0","volume":"13","author":"W Zhu","year":"2023","unstructured":"Zhu W, Ou L, Zhang L, Clark IH, Zhang Y, Zhu X-H, et al. Mapping brain networks in MPS I mice and their restoration following gene therapy. Sci Rep. 2023;13:12716.","journal-title":"Sci Rep"},{"key":"2130_CR50","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13052-018-0565-y","volume":"44","author":"A Fraldi","year":"2018","unstructured":"Fraldi A, Serafini M, Sorrentino NC, Gentner B, Aiuti A, Bernardo ME. Gene therapy for mucopolysaccharidoses: in vivo and ex vivo approaches. Ital J Pediatr. 2018;44:130.","journal-title":"Ital J Pediatr"},{"key":"2130_CR51","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.gene.2018.08.004","volume":"678","author":"TG de Carvalho","year":"2018","unstructured":"de Carvalho TG, Schuh R, Pasqualim G, Pellenz FM, Filippi-Chiela EC, Giugliani R, et al. CRISPR-Cas9-mediated gene editing in human MPS I fibroblasts. Gene. 2018;678:33\u20137.","journal-title":"Gene"},{"key":"2130_CR52","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jconrel.2018.08.031","volume":"288","author":"RS Schuh","year":"2018","unstructured":"Schuh RS, Poletto \u00c9, Pasqualim G, Tavares AMV, Meyer FS, Gonzalez EA, et al. In vivo genome editing of mucopolysaccharidosis I mice using the CRISPR\/Cas9 system. J Control Release. 2018;288:23\u201333.","journal-title":"J Control Release"},{"key":"2130_CR53","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/978-3-319-48382-5_8","volume":"960","author":"AB Engin","year":"2017","unstructured":"Engin AB. What is lipotoxicity? Adv Exp Med Biol. 2017;960:197\u2013220.","journal-title":"Adv Exp Med Biol"},{"key":"2130_CR54","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jcis.2020.05.002","volume":"576","author":"JB Strachan","year":"2020","unstructured":"Strachan JB, Dyett BP, Nasa Z, Valery C, Conn CE. Toxicity and cellular uptake of lipid nanoparticles of different structure and composition. J Colloid Interface Sci. 2020;576:241\u201351.","journal-title":"J Colloid Interface Sci"},{"key":"2130_CR55","doi-asserted-by":"publisher","unstructured":"Macedo HM, Mart\u00ednez E, Barrias C, Sarmento B. Development of an improved 3D in vitro intestinal model to perform permeability studies of paracellular compounds. Front Bioeng Biotechnol. 2020;8:524018. https:\/\/doi.org\/10.3389\/fbioe.2020.524018.","DOI":"10.3389\/fbioe.2020.524018"},{"key":"2130_CR56","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.ymgme.2011.12.012","volume":"105","author":"MF Coutinho","year":"2012","unstructured":"Coutinho MF, Prata MJ, Alves S. Mannose-6-phosphate pathway: a review on its role in lysosomal function and dysfunction. Mol Genet Metab. 2012;105:542\u201350.","journal-title":"Mol Genet Metab"},{"key":"2130_CR57","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ymgme.2012.07.012","volume":"107","author":"MF Coutinho","year":"2012","unstructured":"Coutinho MF, Prata MJ, Alves S. A shortcut to the lysosome: the mannose-6-phosphate-independent pathway. Mol Genet Metab. 2012;107:257\u201366.","journal-title":"Mol Genet Metab"},{"key":"2130_CR58","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41580-019-0185-4","volume":"21","author":"A Ballabio","year":"2020","unstructured":"Ballabio A, Bonifacino JS. Lysosomes as dynamic regulators of cell and organismal homeostasis. Nat Rev Mol Cell Biol. 2020;21:101\u201318.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2130_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-020-0141-7","volume":"6","author":"W-Y Yim","year":"2020","unstructured":"Yim W-Y, Mizushima N. Lysosome biology in autophagy. Cell Discov. 2020;6:6.","journal-title":"Cell Discov"},{"key":"2130_CR60","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/s41580-024-00757-5","volume":"25","author":"RA Nixon","year":"2024","unstructured":"Nixon RA, Rubinsztein DC. Mechanisms of autophagy\u2013lysosome dysfunction in neurodegenerative diseases. Nat Rev Mol Cell Biol. 2024;25:926\u201346.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2130_CR61","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/471325","volume":"2012","author":"MF Coutinho","year":"2012","unstructured":"Coutinho MF, Lacerda L, Alves S. Glycosaminoglycan storage disorders: a review. Biochem Res Int. 2012;2012:471325.","journal-title":"Biochem Res Int"},{"key":"2130_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.107906","volume":"300","author":"SJ Kierans","year":"2024","unstructured":"Kierans SJ, Taylor CT. Glycolysis: a multifaceted metabolic pathway and signaling hub. J Biol Chem. 2024;300:107906.","journal-title":"J Biol Chem"},{"key":"2130_CR63","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41580-023-00676-x","volume":"25","author":"C Settembre","year":"2024","unstructured":"Settembre C, Perera RM. Lysosomes as coordinators of cellular catabolism, metabolic signalling and organ physiology. Nat Rev Mol Cell Biol. 2024;25:223\u201345.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2130_CR64","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nrm2256","volume":"8","author":"B D\u2019Autr\u00e9aux","year":"2007","unstructured":"D\u2019Autr\u00e9aux B, Toledano MB. ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol. 2007;8:813\u201324.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2130_CR65","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.cellsig.2012.01.008","volume":"24","author":"PD Ray","year":"2012","unstructured":"Ray PD, Huang B-W, Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal. 2012;24:981\u201390.","journal-title":"Cell Signal"},{"key":"2130_CR66","doi-asserted-by":"publisher","first-page":"5616","DOI":"10.3390\/molecules26185616","volume":"26","author":"K Pierzynowska","year":"2021","unstructured":"Pierzynowska K, Gaffke L, Cyske Z, W\u0119grzyn G, Buttari B, Profumo E, et al. Oxidative Stress in Mucopolysaccharidoses: Pharmacological Implications. Molecules. 2021;26:5616.","journal-title":"Molecules"},{"key":"2130_CR67","doi-asserted-by":"publisher","first-page":"4244","DOI":"10.1074\/jbc.RA118.001777","volume":"293","author":"B Lloyd-Lewis","year":"2018","unstructured":"Lloyd-Lewis B, Krueger CC, Sargeant TJ, D\u2019Angelo ME, Deery MJ, Feret R, et al. Stat3-mediated alterations in lysosomal membrane protein composition. J Biol Chem. 2018;293:4244\u201361.","journal-title":"J Biol Chem"},{"key":"2130_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9082596","volume":"9","author":"KM Stepien","year":"2020","unstructured":"Stepien KM, Roncaroli F, Turton N, Hendriksz CJ, Roberts M, Heaton RA, et al. Mechanisms of mitochondrial dysfunction in lysosomal storage disorders: a review. J Clin Med. 2020;9:2596.","journal-title":"J Clin Med"},{"key":"2130_CR69","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3390\/ijms24010477","volume":"24","author":"AF Leal","year":"2023","unstructured":"Leal AF, Benincore-Fl\u00f3rez E, Rintz E, Herre\u00f1o-Pach\u00f3n AM, Celik B, Ago Y, et al. Mucopolysaccharidoses: Cellular Consequences of Glycosaminoglycans Accumulation and Potential Targets. IJMS. 2023;24:477.","journal-title":"IJMS"},{"key":"2130_CR70","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11011-025-01605-x","volume":"40","author":"CV Pinheiro","year":"2025","unstructured":"Pinheiro CV, Ribeiro RT, Roginski AC, Brondani M, Zemnia\u00e7ak \u00c2B, Hoffmann CIH, et al. Disturbances in mitochondrial quality control and mitochondria-lysosome contact underlie the cerebral cortex and heart damage of mucopolysaccharidosis type II mice. Metab Brain Dis. 2025;40:177.","journal-title":"Metab Brain Dis"},{"key":"2130_CR71","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1179\/135100001101536094","volume":"6","author":"UT Brunk","year":"2001","unstructured":"Brunk UT, Neuzil J, Eaton JW. Lysosomal involvement in apoptosis. Redox Rep. 2001;6:91\u20137.","journal-title":"Redox Rep"},{"key":"2130_CR72","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/tra.12587","volume":"19","author":"B Cabukusta","year":"2018","unstructured":"Cabukusta B, Neefjes J. Mechanisms of lysosomal positioning and movement. Traffic. 2018;19:761\u20139.","journal-title":"Traffic"},{"key":"2130_CR73","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.tibs.2019.11.003","volume":"45","author":"O Moujaber","year":"2020","unstructured":"Moujaber O, Stochaj U. The cytoskeleton as regulator of cell signaling pathways. Trends Biochem Sci. 2020;45:96\u2013107.","journal-title":"Trends Biochem Sci"},{"key":"2130_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/cells12131782","volume":"12","author":"L Gaffke","year":"2023","unstructured":"Gaffke L, Rintz E, Pierzynowska K, W\u0119grzyn G. Actin cytoskeleton polymerization and focal adhesion as important factors in the pathomechanism and potential targets of mucopolysaccharidosis treatment. Cells. 2023;12:1782.","journal-title":"Cells"},{"key":"2130_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/genes14020272","volume":"14","author":"G Guan","year":"2023","unstructured":"Guan G, Cannon RD, Coates DE, Mei L. Effect of the Rho-Kinase\/ROCK signaling pathway on cytoskeleton components. Genes (Basel). 2023;14:272.","journal-title":"Genes (Basel)"},{"key":"2130_CR76","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1189\/jlb.72.6.1092","volume":"72","author":"E Garc\u00eda-Garc\u00eda","year":"2002","unstructured":"Garc\u00eda-Garc\u00eda E, Rosales C. Signal transduction during Fc receptor-mediated phagocytosis. J Leukoc Biol. 2002;72:1092\u2013108.","journal-title":"J Leukoc Biol"},{"key":"2130_CR77","doi-asserted-by":"publisher","first-page":"56","DOI":"10.4161\/org.19813","volume":"8","author":"HY Kim","year":"2012","unstructured":"Kim HY, Nelson CM. Extracellular matrix and cytoskeletal dynamics during branching morphogenesis. Organogenesis. 2012;8:56\u201364.","journal-title":"Organogenesis"},{"key":"2130_CR78","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/35099066","volume":"2","author":"B Geiger","year":"2001","unstructured":"Geiger B, Bershadsky A, Pankov R, Yamada KM. Transmembrane crosstalk between the extracellular matrix and the cytoskeleton. Nat Rev Mol Cell Biol. 2001;2:793\u2013805.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2130_CR79","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0000000000000108","author":"B Yue","year":"2014","unstructured":"Yue B. Biology of the extracellular matrix: an overview. J Glaucoma. 2014. https:\/\/doi.org\/10.1097\/IJG.0000000000000108.","journal-title":"J Glaucoma"},{"key":"2130_CR80","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nrm3904","volume":"15","author":"C Bonnans","year":"2014","unstructured":"Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol. 2014;15:786\u2013801.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2130_CR81","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S0002-9440(10)64961-9","volume":"156","author":"A Hinek","year":"2000","unstructured":"Hinek A, Wilson SE. Impaired elastogenesis in Hurler Disease. Am J Pathol. 2000;156:925\u201338.","journal-title":"Am J Pathol"},{"key":"2130_CR82","doi-asserted-by":"publisher","first-page":"19740","DOI":"10.1074\/jbc.M600801200","volume":"281","author":"Y Nishitani","year":"2006","unstructured":"Nishitani Y, Maruyama D, Nonaka T, Kita A, Fukami TA, Mio T, et al. Crystal Structures of N-Acetylglucosamine-phosphate Mutase, a Member of the \u03b1-d-Phosphohexomutase Superfamily, and Its Substrate and Product Complexes. J Biol Chem. 2006;281:19740\u20137.","journal-title":"J Biol Chem"},{"key":"2130_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113427","volume":"143","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Li X, Guo W, Huang Z. Enhancing GFPT1 expression with glutamine protects chondrocytes in osteoarthritis. Int Immunopharmacol. 2024;143:113427.","journal-title":"Int Immunopharmacol"},{"key":"2130_CR84","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.bbrc.2023.04.093","volume":"665","author":"L Gaffke","year":"2023","unstructured":"Gaffke L, Pierzynowska K, Cyske Z, Podlacha M, W\u0119grzyn G. Contribution of vesicle trafficking dysregulation to the pathomechanism of mucopolysaccharidosis. Biochem Biophys Res Commun. 2023;665:107\u201317.","journal-title":"Biochem Biophys Res Commun"},{"key":"2130_CR85","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a022616","volume":"6","author":"A Wandinger-Ness","year":"2014","unstructured":"Wandinger-Ness A, Zerial M. Rab proteins and the compartmentalization of the endosomal system. Cold Spring Harb Perspect Biol. 2014;6:a022616.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2130_CR86","unstructured":"Rab7 Protein. - an overview | ScienceDirect Topics [Internet]. [cited 2025 Mar 23]. Available from: https:\/\/www.sciencedirect.com\/topics\/neuroscience\/rab7-protein"},{"key":"2130_CR87","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/978-981-10-4567-7_10","volume":"997","author":"WM Henne","year":"2017","unstructured":"Henne WM. Discovery and roles of ER-endolysosomal contact sites in disease. Adv Exp Med Biol. 2017;997:135\u201347.","journal-title":"Adv Exp Med Biol"},{"key":"2130_CR88","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jconrel.2023.12.045","volume":"366","author":"E Zhang","year":"2024","unstructured":"Zhang E, Zhu H, Song B, Shi Y, Cao Z. Recent advances in oral insulin delivery technologies. J Control Release. 2024;366:221\u201330.","journal-title":"J Control Release"},{"key":"2130_CR89","first-page":"307","volume":"7","author":"N Dan","year":"2020","unstructured":"Dan N, Samanta K, Almoazen H. An update on pharmaceutical strategies for oral delivery of therapeutic peptides and proteins in adults and pediatrics. Child (Basel). 2020;7:307.","journal-title":"Child (Basel)"},{"key":"2130_CR90","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1016\/j.apsb.2020.12.022","volume":"11","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Lu Y, Qi J, Wu W. An update on oral drug delivery via intestinal lymphatic transport. Acta Pharm Sin B. 2021;11:2449\u201368.","journal-title":"Acta Pharm Sin B"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02130-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-026-02130-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02130-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T19:02:04Z","timestamp":1781982124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-026-02130-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":90,"alternative-id":["2130"],"URL":"https:\/\/doi.org\/10.1007\/s13346-026-02130-9","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]},"assertion":[{"value":"6 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Analyses were performed, with informed consent, using fibroblast cell samples from 4 untreated MPS-I patients. The cells were provided by biobanknetwork.telethon.it with prior authorization from that institution\u2019s ethics committee (Comit\u00e9 de \u00e9tica de la investigaci\u00f3n de Santiago-Lugo (CEI-SL) registration code: 2023\/436).Experiments were carried out in accordance with the European Union Directive 2010\/63\/EU for animal experiments and were approved by the Galician Network Committee for Ethics Research (15012\/2025\/003).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"No research involving human subjects was conducted.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The NLC formulation described in this study has been granted a patent in Europe (EP3820455) and the United States US (11,998,643B2).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patent"}}]}}